MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2–Positive and/or Hormone Receptor–Negative Breast Cancers in the I-SPY 2 Trial

PURPOSE: The phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin is a key pathway of survival and therapeutic resistance in breast cancer. We evaluated the pan-Akt inhibitor MK-2206 in combination with standard therapy in patients with high-risk early-stage breast cancer. PATIENTS AND ME...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:J Clin Oncol
Autores principales: Chien, A. Jo, Tripathy, Debasish, Albain, Kathy S., Symmans, W. Fraser, Rugo, Hope S., Melisko, Michelle E., Wallace, Anne M., Schwab, Richard, Helsten, Teresa, Forero-Torres, Andres, Stringer-Reasor, Erica, Ellis, Erin D., Kaplan, Henry G., Nanda, Rita, Jaskowiak, Nora, Murthy, Rashmi, Godellas, Constantine, Boughey, Judy C., Elias, Anthony D., Haley, Barbara B., Kemmer, Kathleen, Isaacs, Claudine, Clark, Amy S., Lang, Julie E., Lu, Janice, Korde, Larissa, Edmiston, Kirsten K., Northfelt, Donald W., Viscusi, Rebecca K., Yee, Douglas, Perlmutter, Jane, Hylton, Nola M., van’t Veer, Laura J., DeMichele, Angela, Wilson, Amy, Peterson, Garry, Buxton, Meredith B., Paoloni, Melissa, Clennell, Julia, Berry, Scott, Matthews, Jeffrey B., Steeg, Katherine, Singhrao, Ruby, Hirst, Gillian L., Sanil, Ashish, Yau, Christina, Asare, Smita M., Berry, Donald A., Esserman, Laura J.
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society of Clinical Oncology 2020
Materias:
ORIGINAL REPORTS
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7106976/
https://ncbi.nlm.nih.gov/pubmed/32031889
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.19.01027
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares